Latest Biotech News

Page 4 of 36
Noxopharm Limited's CEO and Managing Director Dr Gisela Mautner has resigned after four years with the company, including leading a key strategic pivot. The biotech firm plans to announce her successor shortly.
Ada Torres
Ada Torres
14 Apr 2026
Vectus Biosystems has completed the sale of its VB4-P5 renal fibrosis compound to Canadian biotech XORTX, receiving a near 10% equity stake and warrants. This move aligns with Vectus’ strategy to develop drug candidates to a stage attractive to partners while focusing on its lead compound VB0004.
Ada Torres
Ada Torres
14 Apr 2026
BluGlass has secured an upsized A$8 million placement, including a A$2.3 million cornerstone investment from its board and management, to accelerate its gallium nitride laser manufacturing and support a growing project pipeline.
Sophie Babbage
Sophie Babbage
13 Apr 2026
Telix Pharmaceuticals and Regeneron have entered a strategic collaboration to co-develop next-generation radiopharmaceutical therapies, with Telix receiving a $40 million upfront payment and potential milestones exceeding $2 billion.
Ada Torres
Ada Torres
13 Apr 2026
BluGlass Limited (ASX: BLG) has entered a A$1.3 million strategic collaboration with a Fortune 500 global data storage company to advance photonics research using its proprietary visible laser technology.
Sophie Babbage
Sophie Babbage
7 Apr 2026
Pathkey.AI has secured a significant commercial contract with Imunexus Therapeutics, deploying its AI-driven TrialKey platform to enhance early-phase clinical trial design and capital raising efforts.
Sophie Babbage
Sophie Babbage
2 Apr 2026
Bioxyne Ltd has secured a manufacturing agreement with global cannabis giant Aurora Cannabis, marking a major step in its international expansion of pharmaceutical-grade medicinal cannabis products.
Ada Torres
Ada Torres
1 Apr 2026
Racura Oncology has enrolled the first patient in its Phase 1 HARNESS-1 trial, testing RC220 alongside osimertinib to tackle resistance in EGFR-mutant non-small cell lung cancer. This milestone sets the stage for a multi-centre study aiming to improve treatment outcomes.
Ada Torres
Ada Torres
31 Mar 2026
Patrys Limited is advancing a proprietary injectable formulation of quetiapine aimed at the large and underserved delirium treatment market, leveraging an accelerated FDA approval pathway and extensive existing safety data.
Ada Torres
Ada Torres
31 Mar 2026
Genetic Signatures is undertaking a major organisational restructure to cut costs by $5 million and sharpen its commercial focus, aiming to accelerate growth in its diagnostic product offerings.
Ada Torres
Ada Torres
30 Mar 2026
Cynata Therapeutics has completed the 100-day primary evaluation period for its Phase 2 trial of CYP-001 in acute graft versus host disease, with results expected in June 2026. This milestone marks a critical step for the biotech’s lead cell therapy candidate in a condition with few effective treatments.
Ada Torres
Ada Torres
30 Mar 2026
Recce Pharmaceuticals is progressing its Phase 3 clinical trial of RECCE 327, a novel synthetic antibiotic targeting multidrug-resistant infections, with interim data from Indonesia supporting registration plans across ASEAN by 2026.
Ada Torres
Ada Torres
19 Mar 2026